Medical research
Retina UK has invested more than £16million into cutting-edge research since the charity was founded in 1976.
Search
Search results
Webinar: Inflammation and retinal degeneration in RP
Inflammation and retinal degeneration in retinitis pigmentosa: Can lessons learned in the lab help us identify treatments in the clinic?
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Disappointing news from ProQR clinical trial for LCA10
ProQR has published the top-line results from its Phase 2/3 “Illuminate” trial of the RNA therapy sepofarsen for Leber congenital amaurosis type 10 caused by a specific mutation in the CEP290 gene.
Choroideremia
Choroideremia is a genetic condition that causes progressive vision loss, mostly in males, and is due to degeneration of the specialised light-sensing photoreceptor cells that line the back of the eye.
Achromatopsia
Achromatopsia is a rare hereditary vision disorder resulting in an absence of colour vision along with additional visual problems.
e-Newsletter – May 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Research brings hope for the future
“All the promising research makes you feel like there is light at the end of that very dark tunnel after all.”
Does gene therapy always have to be gene-specific?
Early 2020 marked an important milestone for the Retina UK community, when the first person with an inherited retinal condition received NHS treatment to potentially slow or even stop the progression of their sight loss.
Leber Congenital Amaurosis (LCA)
Leber Congenital Amaurosis (LCA) is a rare genetic eye disease that appears at birth or in the first few months of life.